

RESTART OF THE BUYBACK PROGRAM

Saluggia, May 10, 2024 – DiaSorin S.p.A. (FTSE MIB: DIA) (the “**Company**”) announces the restarting from May 13, 2024, of the buyback program already disclosed to the market on May 8, 2023 and based upon the authorization approved by the Shareholders Meeting held on April 28, 2023, for the purposes envisaged by art. 5 of Regulation (EU) n. 596/2014 and, in particular, in order to fulfill the obligations deriving from the stock incentive program dedicated to key executives of DiaSorin S.p.A. and of the companies directly or indirectly controlled by it, called the “Stock Option Plan 2023 - DIASORIN S.p.A.”, approved by the aforementioned Shareholders’ Meeting, as well as serving the other various incentive plans approved by the Company.

The purchases will be made according to the modalities and within the terms established by the aforementioned resolution of the Shareholders’ Meeting, in compliance with the trading conditions set forth by art. 3 of (UE) Delegated regulation 2016/1052 for an overall amount of 80,00 shares, equal to 0.1430% of the share capital, taking into account that, with respect to the maximum quantity (n. 610,000 ordinary shares of the Company, equal to 1.090%), at the date thereof the Company has already purchased no. 300,000 shares, equal to 0.5362% of the share capital.

The purchases will take place at a consideration not exceeding the highest price between the price of the last independent transaction and the price of the highest independent offer current in the trading venues where the purchase is made, it being understood that the unit price cannot in any case be lower by a minimum of 15% and higher by a maximum of 15% compared to the official DiaSorin share price of the trading session preceding each individual purchase transaction.

In the case of purchases, DiaSorin will communicate the details of the purchases made and any other element required by the applicable legislation by the end of the seventh trading day following the execution date of the transaction. Any subsequent changes to the aforementioned purchase program and to the information already published will be promptly communicated by the Company.

It should also be noted that as of today the Company holds no. 2,583,579 treasury shares in portfolio, equal to approximately 4.6178% of the share capital.

For any further detail, please refer to the relative Explanatory Report of the Board of Directors pursuant to art. 125-ter Legislative Decree 58/1998, available on the Company's website www.diasorin.com (Section Company/Governance/Shareholders' Meeting/2023).

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst
eugenia.ragazzo@diasorin.it